It’s only fair to share… Difamilast FDA 2026, APPROVALS 2026, difamilast, Adquey, 2/12/2026, To treat mild to moderate atopic dermatitis PMDA Moizerto, JAPAN APPROVED 2021/9/27 ジファミラスト ディファミラスト; 地法米司特 N-({2-[4-(difluoromethoxy)-3-(propan-2-yloxy)phenyl]-1,3- oxazol-4-yl}methyl)-2-ethoxybenzamide OPA-15406 Formula C23H24F2N2O5 CAS 937782-05-3 Mol weight 446.4439 MM 36; MM-36-Medimetriks-Pharmaceuticals; Moizerto; OPA-15406 Efficacy Anti-inflammatory, Phosphodiesterase IV inhibitor Comment Treatment of atopic dermatitis OriginatorOtsuka Pharmaceutical Development …